Literature DB >> 188996

The ethnic distribution of primary central nervous system tumors: AFIP, 1958 to 1970.

K J Fan, J Kovi, K M Earle.   

Abstract

A retrospective ethnic study was made of 16,311 cases of primary central nervous system (CNS) tumors seen at the Armed Forces Institute of Pathology (AFIP), Washington, D.C., from 1958 to 1970. Results showed a considerably higher Caucasian:Negro (C:N) case ratio (13.7:1) than the C:N population ratio (8.4:1), indicating a higher relative frequency of primary CNS tumors in American Caucasians as compared to American Negroes. The glioma was significantly more frequent in Caucasians than in Negroes (p less than 0.005). In contrast, Negroes had an excess of the pituitary adenoma as compared to Caucasians (P less than 0.01). The proportional frequencies of the meningioma and the nerve sheath tumor were also higher in Negroes than in Caucasians. When this pattern of the tumor distribution of American Negroes was compared to that of African Negroes (a composite African series), the preponderance of the pituitary adenoma and the meningioma and the relative paucity of the glioma in the Negro race as compared to Caucasians were again confirmed. The differences in the relative frequency and the tumor distribution between American Negroes and Caucasians and the considerable similarity of the tumor distribution between American and African Negroes emphasize the importance of genetic factors in the development of at least some primary CNS tumors.

Entities:  

Mesh:

Year:  1977        PMID: 188996     DOI: 10.1097/00005072-197701000-00005

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  12 in total

1.  Low incidence of brain tumors among Ethiopian immigrants in Israel.

Authors:  Lee Yaari; Ora Paltiel; Micha Barchana; Irena Liphshiz; Yigal Shoshan
Journal:  J Neurooncol       Date:  2010-06-08       Impact factor: 4.130

2.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Authors:  Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

3.  Early vs. delayed radiotherapy in a small cohort of patients with supratentorial low grade glioma.

Authors:  J P Knisely; B G Haffty; S R Christopher
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

Review 4.  Environmental risk factors for primary malignant brain tumors: a review.

Authors:  M Wrensch; M L Bondy; J Wiencke; M Yost
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

5.  Brain tumors diagnosed in the first year of life in five Far-Eastern countries. Statistical analysis of 307 cases.

Authors:  S Oi; S Matsumoto; J U Choi; J K Kang; T Wong; C Wang; T S Chan
Journal:  Childs Nerv Syst       Date:  1990-03       Impact factor: 1.475

6.  Is there a genetic basis for the differences in cancer incidence between Afro-Americans and Euro-Americans?

Authors:  A Goldson; U Henschke; L D Leffall; R L Schneider
Journal:  J Natl Med Assoc       Date:  1981-08       Impact factor: 1.798

7.  Ethnic distribution of primary central nervous system tumors in Washington, DC, 1971 to 1985.

Authors:  K J Fan; G H Pezeshkpour
Journal:  J Natl Med Assoc       Date:  1992-10       Impact factor: 1.798

8.  Effect of dietary vitamin A or N-acetylcysteine on ethylnitrosourea-induced rat gliomas.

Authors:  D A Ross; P Kish; K M Muraszko; M Blaivas; M Strawderman
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

9.  Metastatic brain tumors in two predominantly black hospitals: a statistical analysis.

Authors:  K J Fan; J Kovi
Journal:  J Natl Med Assoc       Date:  1979-07       Impact factor: 1.798

10.  Incidence of first primary central nervous system tumors in California, 2001-2005.

Authors:  Monica Brown; Rudolph Schrot; Katrina Bauer; Deanna Letendre
Journal:  J Neurooncol       Date:  2009-04-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.